Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Applying Precision Medicine in Glioblastoma: New and Emerging Therapeutic Targets
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: May 19, 2022 Expiration: May 18, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Karyopharm Therapeutics Inc.
Sumitomo Dainippon Pharma Oncology, Inc.
Andrew B. Lassman, MD
Program Director
Timothy Cloughesy, MD
Rimas V. Lukas, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate new targeted therapeutic agents into clinical practice for patients with GBM based on individual patient and tumor characteristics
  • Identify which biomarkers should be assessed in patients with newly diagnosed and recurrent GBM
  • Describe the rationale for targeting NTRK gene fusion in GBM and the effects of NTRK fusions on standard treatment selection
  • Discuss the current and emerging clinical data on promising small-molecule TKIs and other therapies for specific targets in the treatment of recurrent GBM
  • Select optimal treatment for patients with recurrent GBM based on current evidence and molecular markers
  • Refer appropriate patients with GBM for enrollment on a clinical trial

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Andrew B. Lassman, MD

Chief, Neuro-Oncology Division
Department of Neurology
Columbia University Irving Medical Center
New York, New York

Andrew B. Lassman, MD, has disclosed that he has received research support paid to his institution from AbbVie, Aeterna Zenaris, Bayer, Beigene, Bristol-Myers Squibb, Chimerix, Corden, DelMar, Genentech/Roche, Kadmon, Karyopharm, Kazia, Millennium, NextSource, Novartis, Novocure, Orbus, Pfizer, QED, Semus, Servier, and VBI Vaccines; has received consulting fees from Bayer, Bioclinica, Karyopharm, Novocure, Orbus, Sapience, and Vivacitas; and has received travel/in-kind support from AbbVie, Karyopharm, Novartis, Pfizer, QED, and VBI Vaccines.

Faculty

Timothy Cloughesy, MD

Professor and Director
Department of Neurology, Neuro-Oncology Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Timothy Cloughesy, MD, has disclosed that he is cofounder, major stock holder, consultant, and board member of Katmai Pharmaceuticals; member of the board for the 501c3 Global Coalition for Adaptive Research; holds stock options in Notable Labs; holds stock in Chimerix and receives milestone payments and possible future royalties; is a member of the scientific advisory board for Cure Brain Cancer Foundation and Break Through Cancer; has provided paid consulting services to AbbVie, Agios, Amgen, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Boston Biomedical, BrainStorm, Celgene, Cortice, Deciphera, DNATrix, Gan & Lee, GCAR, Genocea, GW Pharma, Human Longevity, Immvira, Inovio, Insys, Jubilant, Karyopharm, Katmai, Kintara, Kiyatec, Lilly, Medefield, Medqia Trizel, Medscape, Merck, Notable labs, Novartis, Novocure, Novogen, Odonate Therapeutics QED, Pascal Biosciences, Pfizer, ProNai, Puma, Roche, Sapience, SDP, Sunovion, Tocagen, Tyme, VBI, VBL, Vigeo Therapeutics, and Wellcome Trust; and has contracts with UCLA for the Brain Tumor Program with AbbVie, Agios, Amgen, AstraZeneca, Beigene, Bristol-Myers Squibb, Boston Biomedical, Deciphera, DNATrix, Karyopharm, Kazia, Merck, Novartis, Oncoceutics, Oncovir, Orbus, and Tocagen.
Rimas V. Lukas, MD

Associate Professor of Neurology (Neuro-oncology)
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Rimas V. Lukas, MD, has disclosed that he has served on speaker’s bureaus for Merck and Novocure and received drug-only support for a clinical trial from Bristol-Myers Squibb.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for medical oncologists, neuro-oncologists, and other healthcare professionals who care for patients with GBM.

Goal

The goal of this program is to improve the knowledge, confidence, and competence of learners to apply recent findings and integrate new and emerging agents into the treatment of patients with GBM.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 19, 2022, through May 18, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Applying Precision Medicine in Glioblastoma: New and Emerging Therapeutic Targets
  • CME

Loading...
In this interactive webcast capturing a live CCO symposium, experts share key data and clinical strategies for incorporating novel targeted therapies into the management of glioblastoma.
Andrew B. Lassman, MD
Program Director
Timothy Cloughesy, MD
Rimas V. Lukas, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: May 19, 2022 Expiration: May 18, 2023

Related Content

Expert-selected slides on new and emerging targeted therapies for glioblastoma, from Clinical Care Options (CCO).

Timothy Cloughesy, MD Andrew B. Lassman, MD Rimas V. Lukas, MD Released: April 12, 2022

Expert-selected slides on optimal treatment of patients with glioblastoma, from Clinical Care Options (CCO).

Andrew B. Lassman, MD Released: April 5, 2022

Expert-selected slides on clinical trial strategies for glioblastoma, from Clinical Care Options (CCO).

Timothy Cloughesy, MD Released: April 5, 2022

Expert-selected slides on new and emerging targeted therapies for glioblastoma, from Clinical Care Options (CCO).

Rimas V. Lukas, MD Released: April 5, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Karyopharm Therapeutics Inc.
Sumitomo Dainippon Pharma Oncology, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings